Patents Examined by Enrique D. Longton
  • Patent number: 5989893
    Abstract: The invention discloses a chimeric GLUT transporter including a GLUT receptor polypeptide fused to a domain of a detectable heterologous polypeptide and cells expressing such reporter constructs. Cells expressing a detectably-tagged chimeric GLUT transporter are used in methods of screening candidate compounds for their ability to agonize or antagonize an interaction between a ligand and a receptor, e.g., insulin. In addition, a 30 amino acid intracellular retention sequence is disclosed.
    Type: Grant
    Filed: August 8, 1994
    Date of Patent: November 23, 1999
    Assignee: University of Massachusetts Medical Center
    Inventors: Michael P. Czech, Silvia Corvera
  • Patent number: 5985602
    Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.
    Type: Grant
    Filed: September 27, 1996
    Date of Patent: November 16, 1999
    Assignee: Genetics Institute, Inc.
    Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, David Merberg, Maurice Treacy, Vikki Spaulding, Cheryl Evans
  • Patent number: 5986062
    Abstract: Human serum albumin obtained by gene manipulation techniques can be purified by a combination of specified steps in which a culture supernatant obtained from a human serum albumin-producing host is subjected to ultrafiltration, heat treatment, acid treatment and another ultrafiltration, followed by subsequent treatments with a cation exchanger, a hydrophobic chromatography carrier and an anion exchanger, and by salting-out to thereby obtain a pure form of human serum albumin which contains substantially no proteinous and polysaccharide contaminants, which is formulated into a pharmaceutical preparation. The thus obtained human serum albumin can further be purified by treating recombinant human serum albumin with a hydrophobic chromatography carrier at pH of 2 to 5 and a salt concentration of 0.4 to 1 and exposing the carrier to a pH of 6 to 8 and a salt concentration of 0.01 to 0.
    Type: Grant
    Filed: October 3, 1995
    Date of Patent: November 16, 1999
    Assignee: The Green Cross Corporation
    Inventors: Takao Ohmura, Akinori Sumi, Wataru Ohtani, Naoto Furuhata, Kazuya Takeshima, Kaeko Kamide, Munehiro Noda, Masahide Kondo, Syoichi Ishikawa, Kazuhiro Oohara, Kazumasa Yokoyama, Nagatoshi Fujiwara
  • Patent number: 5985606
    Abstract: The invention provides a human preprotachykinin B (PPT-B) and polynucleotides which identify and encode PPT-B. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PPT-B.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: November 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal, Matthew R. Kaser
  • Patent number: 5985590
    Abstract: CrFC21 cDNA was cloned into two mammalian vectors: pCIneo and pCDNAI, both of which carry the strong CMV promoter for expression in mammalian cell lines. Various CrFC cDNA constructs transformed into P. pastoris and S. cerevisiae were expressed to yield full-length recombinant Factor C (rCrFC) protein of .about.130 kDa which is immunoreactive. The rCrFC is expressed in an intracellular, insoluble form. Intracellular localization of the nascent protein provides protection from premature digestion by proteases secreted by the host cell. Subsequent to its synthesis, rCrFC is solubilized and purified under pyrogen-free conditions. Using established protocols, the protein can be denatured and renatured to recover its biological functionality. By manipulation of the 5' end of CrFC26, truncated constructs containing this cDNA are expressed by S. cerevisiae to give immunoreactive rCrFC. The rCrFC produced from both CrFC21 and CrFC26 constructs, solubilized by Triton X-100 or SDS, is found to be immunoreactive.
    Type: Grant
    Filed: June 18, 1997
    Date of Patent: November 16, 1999
    Assignee: National University of Singapore
    Inventors: Jeak Ling Ding, Bow Ho
  • Patent number: 5981219
    Abstract: DNA molecules are described which code for a plastid 2-oxoglutarate/malate translocator, particularly from Spinacia oleracea, as well as bacteria, fungi, transgenic plant cells and transgenic plants containing such DNA molecules.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: November 9, 1999
    Assignee: Hoechst Schering Agrevo GmbH
    Inventors: Ulf-Ingo Flugge, Andreas Weber, Karsten Fischer
  • Patent number: 5976837
    Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.
    Type: Grant
    Filed: October 29, 1997
    Date of Patent: November 2, 1999
    Assignee: Genetics Institute, Inc.
    Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, David Merberg, Maurice Treacy, Vikki Spaulding, Michael J. Agostino
  • Patent number: 5976838
    Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: November 2, 1999
    Assignee: Genetics Institute, Inc.
    Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, David Merberg, Maurice Treacy, Vikki Spaulding, Michael J. Agostino
  • Patent number: 5972697
    Abstract: A novel class of NIMA interacting proteins (PIN), exemplified by Pin1, is provided. Pin1 induces a G2 arrest and delays NIMA-induced mitosis when overexpressed, and triggers mitotic arrest and DNA fragmentation when depleted. Methods of identifying other Pin proteins and Pin-interacting proteins and identifying compositions which affect Pin activity or expression are also provided.
    Type: Grant
    Filed: November 13, 1995
    Date of Patent: October 26, 1999
    Assignee: The Salk Institute for Biological Studies
    Inventors: Tony Hunter, Kun Ping Lu
  • Patent number: 5969104
    Abstract: The present invention provides a polynucleotide (mctl) which identifies and encodes a novel human C-type lectin (MCTL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MCTL. The invention also provides for the use of substantially purified MCTL and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of MCTL. Additionally, the invention provides for the use of antisense molecules to mctl in pharmaceutical compositions for treatment of diseases associated with the expression of MCTL. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of mctl. The present invention also relates to anti-MCTL antibodies which specifically bind to MCTL.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: October 19, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Benjamin Graeme Cocks, Surya K. Goli, Jennifer L. Hillman
  • Patent number: 5965388
    Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.
    Type: Grant
    Filed: September 27, 1996
    Date of Patent: October 12, 1999
    Assignee: Genetics Institute, Inc.
    Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, David Merberg, Maurice Treacy, Cheryl Evans, Michael Bowman
  • Patent number: 5965383
    Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus-or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: October 12, 1999
    Assignee: Bio-Technology General Corp.
    Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
  • Patent number: 5965397
    Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.
    Type: Grant
    Filed: January 28, 1998
    Date of Patent: October 12, 1999
    Assignee: Genetics Institute, Inc.
    Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, David Merberg, Maurice Treacy, Vikki Spaulding, Michael J. Agostino
  • Patent number: 5965386
    Abstract: Albumin, for example human albumin, is expressed and secreted in yeast which has been mutated to lack the yeast aspartyl protease 3 (Yap3p) or its equivalent, thereby reducing the production of a 45 kD albumin fragment. A further reduction is achieved by additionally deleting the Kex2p function. Alternatively, a modified albumin is prepared which is not susceptible to Yap3p cleavage, for example human albumin which is R410A, K413Q and K414Q.
    Type: Grant
    Filed: November 11, 1996
    Date of Patent: October 12, 1999
    Assignee: Delta Biotechnology Limited
    Inventors: Sean Martin Kerry-Williams, Sarah Catherine Gilbert
  • Patent number: 5962669
    Abstract: A protein designated Prion Protein Modulator Factor (PPMF) is disclosed which protein is an auxiliary factor in prion replication. PPMF is primarily characterized by its ability to bind to PrP.sup.C and facilitate a conformational change from PrP.sup.C to PrP.sup.Sc. A discontinuous epitope on PrP.sup.C comprising residues 172, 215 and 219 of human PrP.sup.C binds PPMF which is encoded by a nucleotide sequence derived from an organism selected from the group consisting of cow, sheep, mouse, hamster and human. In converting PrP.sup.C to PrP.sup.Sc the PPMF forms a PrP.sup.C /PrP.sup.Sc complex and is a rate limiting compound in the formation of that complex. Molecules, including antibodies, which bind PPMF or its epitope on PrP.sup.C are useful in the treatment of prion disease. Pharmacophores of the PrP.sup.C epitope are disclosed as are useful therapeutics and pharmacophores of the PPMF surface which binds PrP.sup.C. Animals resistant to prion disease are taught as are genes for producing such animals.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: October 5, 1999
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Fred E. Cohen, Thomas L. James, Kiyotoshi Kaneko
  • Patent number: 5962294
    Abstract: DNA isolates coding for sialyltransferase which contain a conserved region of homology and methods of obtaining such DNA are provided, together with expression systems for recombinant production of sialyltransferase.
    Type: Grant
    Filed: August 4, 1993
    Date of Patent: October 5, 1999
    Assignees: The Regents of the University of California, Amgen, Inc.
    Inventors: James C. Paulson, Xiaohong Wen, Brian Livingston, William Gillespie, Sorge Kelm, Alma L. Burlingame, Katalin Medzihradszky
  • Patent number: 5962649
    Abstract: The invention provides a process for purifying recombinant human serum albumin (rHSA) by heating a culture medium containing rHSA and the rHSA-producing host cello, feeding said heated solution upwardly into a fluidized bed in which adsorbent particles are suspended to effect contacting with the adsorbent particles and then recovering the adsorbed fraction containing the rHSA, and a composition comprising rHSA which shows a A35D/A280 ratio of below 0.015, when formulated into a 25% solution of said albumin.
    Type: Grant
    Filed: August 31, 1995
    Date of Patent: October 5, 1999
    Assignee: Yoshitomo Pharmaceutical Industries, Ltd.
    Inventors: Munehiro Noda, Akinori Sumi, Takao Ohmura, Kazumasa Yokoyama
  • Patent number: 5958726
    Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: September 28, 1999
    Assignee: Genetics Institute, Inc.
    Inventors: Kenneth Jacobs, John M. McCoy, Lisa A. Racie, Edward R. LaVallie, David Merberg, Maurice Treacy, Cheryl Evans
  • Patent number: 5955428
    Abstract: The present invention provides a human metallothionein (HMBP-I) and polynucleotides which identify and encode HMBP-I. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HMBP-I and a method for producing HMBP-I. The invention also provides for agonists, antibodies, or antagonists specifically binding HMBP-I, and their use, in the prevention and treatment of diseases associated with expression of HMBP-I. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HMBP-I for the treatment of diseases associated with the expression of HMBP-I. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HMBP-I.
    Type: Grant
    Filed: July 28, 1997
    Date of Patent: September 21, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 5952467
    Abstract: A novel class of NIMA interacting proteins (PIN), exemplified by Pin1, is provided. Pin1 induces a G2 arrest and delays NIMA-induced mitosis when overexpressed, and triggers mitotic arrest and DNA fragmentation when depleted. Methods of identifying other Pin proteins and Pin-interacting proteins and identifying compositions which affect Pin activity or expression are also provided.
    Type: Grant
    Filed: April 24, 1998
    Date of Patent: September 14, 1999
    Assignee: The Salk Institute for Biological Studies
    Inventors: Tony Hunter, Kun Ping Lu